1.22% -0.0079

Biora Therapeutics Inc (BIOR)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Biora Therapeutics Inc Stock (BIOR) Company Profile

Biora Therapeutics Inc

855-293-2639

4330 LA JOLLA VILLAGE DRIVE, SAN DIEGO

Prossima data di guadagno

Ultimi documenti SEC

BIOR's Discussions on Twitter

Biora Therapeutics Inc Borsa (BIOR) Ultime notizie

Biora Therapeutics Inc Azioni (BIOR) Dati Finanziari

Biora Therapeutics Inc (BIOR)

Biora Therapeutics Inc Stock (BIOR) Company Profile

Biora Therapeutics Inc Borsa (BIOR) Ultime notizie

Biora Therapeutics secures additional $4 million financing - Investing.com

Biora Therapeutics Achieves ISO 13485 Certification - GlobeNewswire

Biora Therapeutics Achieves ISO 13485 Certification - StockTitan

A History of Outperforming Analyst Forecasts and Beating the Odds: Biora Therapeutics Inc (BIOR) - SETE News

Biora Therapeutics Announces Positive Nasdaq Listing Decision - GlobeNewswire

Biora Therapeutics Announces Positive Nasdaq Listing Decision - StockTitan

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - The Bakersfield Californian

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Biora Therapeutics secures new financial agreements - Investing.com India

Biora Therapeutics secures new financial agreements - Investing.com

BIOR: Second Quarter Results - Yahoo Finance

Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World

BIOR’s Stock Woes: Down -20.37% in 6 Months, Down -20.37% in Just 5 Days - The InvestChronicle

Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023) - Yahoo Finance

Biora Therapeutics (NASDAQ:BIOR) Receives “Buy” Rating from HC Wainwright - Defense World

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2024 Earnings Call Transcript - Insider Monkey

Biora Therapeutics maintains stock target after strong Q2 results By Investing.com - Investing.com UK

Earnings call: Biora Therapeutics reports progress on BT-600 and BioJet platforms - Investing.com

Biora Therapeutics Inc (BIOR) Q2 2024 Earnings Call Transcript H - GuruFocus.com

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024 - MSN

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024 - InvestorPlace

Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript - Seeking Alpha

Biora Therapeutics Restructures Debt and Issues New Securities - TipRanks

Biora Therapeutics Announces Funding Agreement with Existing Investors - GlobeNewswire

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - StockTitan

Biora Therapeutics Announces Funding Agreement with Existing Investors - StockTitan

Biora Therapeutics (BIOR) Set to Announce Quarterly Earnings on Monday - Defense World

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewswire

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance

Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference - GlobeNewswire

Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference - StockTitan

HC Wainwright Reiterates Buy Rating for Biora Therapeutics (NASDAQ:BIOR) - Defense World

Biora reports promising BT-600 ulcerative colitis trial results - Investing.com

Anchoring Your Portfolio: Is BIOR Stock a Safe Harbor? - The InvestChronicle

Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event - GlobeNewswire

Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as ... - The Bakersfield Californian

Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event - StockTitan

Biora Therapeutics (NASDAQ:BIOR) Stock Price Up 2.3% - Defense World

Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 - Technology Networks

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ - GlobeNewswire

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024 - Yahoo Finance

BIOR: BT-600 Topline - Yahoo Finance

Market Insights: Biora Therapeutics Inc (BIOR)’s Notable Gain of 3.25, Closing at 0.63 - The Dwinnex

A year in review: Biora Therapeutics Inc (BIOR)’s performance in the last year - US Post News

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Quantisnow

BIORBiora Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Biora Therapeutics Reports Promising BT-600 Trial Results - TipRanks

Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 - GlobeNewswire

Biora Therapeutics To Present On The BioJet Systemic Oral Delivery Platform At The Next Gen Peptide Formulation ... - Quantisnow

Biora Therapeutics Inc Azioni (BIOR) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a BIOR